Navigation Links
Cystic Fibrosis: License Agreement Boosts Development of Therapy Against Lung Infections
Date:12/19/2007

ZURICH, Switzerland, December 19 /PRNewswire/ -- An exclusive license for the development and commercialisation of a drug delivery system for lung infections in Cystic Fibrosis patients was signed today. As part of the agreement, aRigen Pharmaceuticals Inc., Japan transferred relevant rights to Axentis Pharma AG of Switzerland. The EMEA has already granted orphan drug status to the licensed technology and a phase II clinical trial will be initiated by Axentis Pharma AG in early 2008.

Axentis Pharma AG (Switzerland) and aRigen Pharmaceuticals, Inc. (Japan) announced today the signature of a license agreement for the development of therapy against lung infections in Cystic Fibrosis patients. Under the terms of the agreement Axentis Pharma AG purchased from aRigen Pharmaceuticals, Inc. an exclusive license for the development and commercialisation of ARB-CF0223 worldwide except Japan and Korea. ARB-CF0223 is a fully patented, innovative encapsulating drug delivery system for the treatment of pulmonary infections in patients with Cystic Fibrosis. The system has an improved safety profile, higher efficacy and lower doses, and also reduces the frequency and severity of exacerbations compared to current treatments for pulmonary infections in patients with Cystic Fibrosis. As part of the agreement aRigen Pharmaceuticals, Inc. received shares of Axentis Pharma plus an undisclosed sum in cash.

Jorg Zielasek, President of Axentis Pharma AG, commented that: "The purchase of the license from aRigen Pharmaceuticals grants Axentis the right to further develop and commercialise an extremely promising treatment for chronic lung inflammation, the most severe consequence of Cystic Fibrosis. The agreement means that Axentis can now initiate an immediate phase II clinical trial in Germany. The design of the study has already been approved by the EMEA, which has also granted orphan drug status to ARB-CF0223. This is a very promising prospect for both Cystic Fibrosis
'/>"/>

SOURCE Axentis Pharma AG
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
2. GeneGo and the Cystic Fibrosis Foundation Collaborate to Advance Understanding of Cystic Fibrosis
3. PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
6. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
7. Pharsight Achieves First License Sale for Public-Source Database
8. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
9. Niceware International Announces Licensed Vendor Status with ICCBBA, Inc. to Provide ISBT 128-compliant Software
10. Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Texas (PRWEB) December 17, 2014 ... on Global Quartz Tubing industry. For an overview ... definition, classification, application, industry chain structure, industry overview, ... quartz tubing industry has witnessed rapid ... a number of acquisitions. This report mentions quartz ...
(Date:12/17/2014)... , Dec. 16, 2014  Vermillion, Inc. (NASDAQ: ... gynecologic disease, today announced the next step in its ... bio-analytics solutions provider with the naming of current Chief ... Chief Executive Officer, while current Chairman of the Board ... serve as Chairman. These changes are effective January 1, ...
(Date:12/17/2014)... Mass. , Dec. 17, 2014   Synageva ... biopharmaceutical company developing therapeutic products for rare disorders, announced ... Conference being held in San Francisco, CA. ... President and Chief Executive Officer, will present on Monday, ... EST).  The presentation will be webcast live and may ...
(Date:12/15/2014)... , Dec. 15, 2014  GlassesOff Inc. (OTCBB: GLSO) ... as an independent director of the Company,s Board ... AeroScout and served as its CEO until its acquisition ... a $240 million transaction. Recognized as the inventor of ... leadership, AeroScout provided Wi-Fi -based RFID solutions focused on ...
Breaking Biology Technology:2020 Quartz Tubing Market: Global Development & Forecasts Analysis Now at DeepResearchReports.com 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3
... ROCKVILLE, Md., July 21 Novavax, Inc. (Nasdaq: ... J. Trizzino as Senior Vice President, International and Government Alliances, ... directly to Dr. Rahul Singhvi, Novavax,s President and Chief Executive ... international alliances with pharmaceutical companies and all governmental agencies, including ...
... NEW YORK, July 21 /PRNewswire-Asia-FirstCall/ -- American ... Company" or "AOBO"), a pharmaceutical,company dedicated to improving ... broad range of prescription and over the counter ... honorably elected as one of,the "Top 20 Most ...
... , PALO ALTO, Calif., July 21, Varian, ... quarter of its fiscal year 2009 after 1:00 p.m. Pacific Time (PT) ... its investor conference call to review those quarterly results is scheduled to ... , That live webcast can be accessed from Varian, Inc.,s ...
Cached Biology Technology:Novavax Announces Appointment of John J. Trizzino as Senior Vice President, International and Government Alliances 2American Oriental Bioengineering Honorably Elected a Top 20 Most Competitive Public Pharmaceutical Company in China 2
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has ... in India 2015-2019" report to their offering. ... this market is the adoption of multimodal biometric ... characteristic of an individual for verification and identification ...
(Date:12/11/2014)... Dec. 10, 2014  Data Sciences International (DSI), ... released a new series of digital telemetry implants ... researchers. M series, part of the PhysioTel™ Digital ... best possible physiologic data when incorporating functional endpoints ... endpoints to toxicology studies has evolved from short ...
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Valencell, a ... it is seeing a staggering demand from its licensees ... the Company revealed, is not solely coming from fitness ... as well. "A wearable is only as ... result, accuracy is the ultimate driver in long-term mass ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... found a mechanism that naturally shuts down cellulose production ... turned on may be key to enhancing biomass production ... botany and plant pathology, said that small-interfering RNAs (siRNAs) ... off genes involved in primary cell wall growth in ...
... Finnish scientists have reported a breakthrough in the attempts ... discovered disturbances in lipid and amino acid metabolism in ... known as juvenile diabetes. The alterations preceded the autoimmune ... new approaches for prediction and prevention of type 1 ...
... is available in French . , ... intelligent design. An evolutionary geneticist from the Universit de ... Lyon and Montpellier, have published a ground-breaking study that ... LUCA (Last Universal Common Ancestor). Their findings, presented in ...
Cached Biology News:Researchers find nature's shut-off switch for cellulose production 2New scientific knowledge on juvenile diabetes 2New scientific knowledge on juvenile diabetes 3Earth's original ancestor was LUCA, not Adam nor Eve 2
S-100A10 (H-80)...
... Shimadzu Biotech presents PsiPort Mass Directed ... review and data acquisition system designed ... for the life science and pharmaceutical ... designed specifically to simplify high throughput ...
SP6 RNA Polymerase, 50 l, 20 U/l ,Cap Scribe Buffer, 100 l, 5x conc....
... catalyzes the transfer of the ... 5-terminus of polynucleotides or to ... The enzyme, purified from recombinant ... to phosphorylate RNA, DNA and ...
Biology Products: